Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...
Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to boost its kidney disease candidates further by going public. The Bay ...
The latest Maze Simulator Codes can help you solve the complicated mazes in this Roblox title, letting you train your problem-solving skills. At first, the sheer quantity of mazes may scare you.
Maze Therapeutics on Tuesday filed plans for an initial public offering that could become the biotechnology sector’s first of the year, depending on how quickly the deal comes together. If Maze is ...